Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results

Kymera Therapeutics (NASDAQ:KYMR) announced its quarterly earnings results on Thursday. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04, Briefing.com reports. The business had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $14.24 million. Kymera Therapeutics had a negative return on equity of 37.83% and a negative net margin of 194.67%. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.70) earnings per share.

Kymera Therapeutics Stock Performance

KYMR opened at $37.40 on Friday. The business has a 50-day moving average of $38.52 and a two-hundred day moving average of $29.33. Kymera Therapeutics has a 12 month low of $9.60 and a 12 month high of $45.31.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $42.85, for a total value of $1,812,640.70. Following the completion of the sale, the insider now owns 4,925,812 shares in the company, valued at approximately $211,071,044.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Jared Gollob sold 46,137 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the completion of the sale, the insider now owns 74,709 shares of the company’s stock, valued at approximately $2,652,169.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the transaction, the insider now directly owns 4,925,812 shares in the company, valued at $211,071,044.20. The disclosure for this sale can be found here. Insiders sold 474,051 shares of company stock worth $19,624,211 in the last 90 days. 16.67% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on KYMR shares. Oppenheimer dropped their price objective on shares of Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research note on Friday. JPMorgan Chase & Co. boosted their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Stifel Nicolaus increased their price objective on Kymera Therapeutics from $35.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Piper Sandler increased their price objective on Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Finally, Wolfe Research began coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.